Baseline saliva level of 3-methoxy-4-hydroxyphenylglycole (MHPG) associates with a consequent cognitive decline in non-demented elderly subjects. Three-years follow-up study

Psychiatry Research

Volumn 195, Issue 3, 2012, Pages 125-128

  Watanabe, Itaru ^a   Li, Guang Ying ^b   Imamura, Yoshiomi ^a   Nabeta, Hiromi ^a   Kunitake, Yutaka ^a   Ishii, Hironobu ^a   Haraguchi, Masanori ^a   Furukawa, Yuzo ^a   Tateishi, Hiroshi ^a   Kojima, Naoki ^c   Nizoguchi, Yoshito ^a   Yamada, Shigeto ^a  

^a SAGA UNIVERSITY   (Japan)

^b CHANGCHUN UNIVERSITY   (China)

^c Kojima Hospital   (Japan)

Author keywords

Elderly subjects; Frontal Assessment Battery; Mini Mental State Examination; Saliva MHPG

Indexed keywords

4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL;

AGED; ARTICLE; COGNITION; COGNITIVE DEFECT; COHORT ANALYSIS; COMMUNITY LIVING; CORRELATION ANALYSIS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; FRONTAL ASSESSMENT BATTERY; HUMAN; MALE; MINI MENTAL STATE EXAMINATION; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PRIORITY JOURNAL; SALIVA LEVEL; SCORING SYSTEM;

AGED; AGED, 80 AND OVER; AGING; COGNITION DISORDERS; COHORT STUDIES; FEMALE; HUMANS; MALE; MENTAL STATUS SCHEDULE; METHOXYHYDROXYPHENYLGLYCOL; NEUROPSYCHOLOGICAL TESTS; SALIVA; SEX FACTORS; STATISTICS, NONPARAMETRIC;

EID: 84857656395     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2011.07.013     Document Type: Article

References (29)

1. Brane G., Gottfries C.G., Blennow K., Karlsson I., Lekman A., Parnetti L., Svennerholm L., Wallin A. Monoamine metabolites in cerebrospinal fluid and behavioral ratings in patients with early and late onset of Alzheimer dementia. Alzheimer Disease and Associated Disorders 1989, 3:148-156.
2. Eisenhofer G., Kopin I., Goldstein D. Catecholamine metabolism: a contemporary view with implications for physiology and medicine. Pharmacological Reviews 2004, 56:331-349.
3. Goldberg J., Breckenridge J., Sheik J. Differences in symptoms of depression and anxiety: examining behavioral medicine outpatients. Journal of Behavioral Medicine 2003, 26:119-131.
4. Hoogendijk W.J., Feenstra M.G., Botterblom M.H., Gilhuis J., Sommer I.E., Kamphorst W., Eikelenboom P., Swaab D.F. Increased activity of surviving locus ceruleus neurons in Alzheimer's disease. Annals of Neurology 1999, 45:82-91.
5. Jossan S., Gillberg G., Gottfries G., Karlsson I., Oreland L. Monoamine oxidase B in brains from patients with Alzheimer's disease. A biochemical and autoradiographical study Neuroscience 1991, 45:1-12.
6. Kawashima R., Okita K., Yamazaki R., Tajima N., Yoshida H., Taira M., Iwata K., Sasaki T., Maeyama K., Usui N., Sugimoto K. Reading aloud and arithmetic calculation improve frontal function of people with dementia. Journals of Gerontology Series A. Biological Sciences and Medical Sciences 2005, 60:380-384.
7. Lawlor B.A., Bierer L.M., Ryan T.M., Schmeidler J., Knott P.J., Williams L.L., Mohs R.C., Davis K.L. Plasma 3-methoxy-4-hydroxyphenylglycol (MHPG) and clinical symptoms in Alzheimer's disease. Biological Psychiatry 1995, 38:185-188.
8. Leckman I.F., Maas J.W., Redmond D.E. Effects of oral slonidine on plasma 3-methoxy-4-hydroxyphenylglycol in men: preliminary report. Life Sciences 1980, 26:2179-2185.
9. Li G.Y., Ueki H., Kawashima T., Sugataka K., Muraoka T., Yamada S. Involvement of the noradrenergic system in performance on a continuous task requiring effortful attention. Neuropsychobiology 2004, 50:336-340.
10. Li G.Y., Ueki H., Yamamoto Y., Yamada S. Association between the scores on the general health questionnaire-28 and the saliva levels of 3-methoxy-4-hydroxyphenylglycol in normal volunteers. Biological Psychology 2006, 73:209-211.
11. Li G.Y., Watanabe I., Kunitake Y., Sugataka K., Muraoka T., Kojima N., Kawashima T., Yamada S. Relationship between saliva level of 3-mrthoxy-4-hydroxyphenylglycol and mental health in the elderly general population. Psychiatry and Clinical Neuroscience 2008, 62:562-567.
12. Liu H.C., Yang J.C., Chang Y.F., Liu T.Y., Chi C.W. Analysis of monoamines in the cerebrospinal fluid of Chinese patients with Alzheimer's disease. Annals of the New York Academy of Sciences 1991, 640:215-218.
13. Maas J.W., Hattox S.E., Landis D.H., Roth R.H. The determination of a brain arteriovenous difference for 3-methoxy-4-hydroxyphenethyleneglycol (MHPG). Brain Research 1976, 118:167-173.
14. Martignoni E., Blandini F., Petraglia F., Pacchetti C., Bono G., Nappi G. Cerebrospinal fluid norepinephrine, 3-methoxy-4-hydroxyphenylglycol and neuropeptide Y levels in Parkinson's disease, multiple system atrophy and dementia of the Alzheimer type. Journal of Neural Transmission. Parkinson's Disease and Dementia Section 1992, 4:191-205.
15. Molchan S.E., Lawlor B.A., Hill J.L., Martinez R.A., Davis C.L., Mellow A.M., Rubinow D.R., Sunderland T. CSF monoamine metabolites and somatostatin in Alzheimer's disease and major depression. Biological Psychiatry 1991, 29:1110-1118.
16. Nazarali A.J., Reynolds G.P. Monoamine neurotransmitters and their metabolites in brain regions in Alzheimer's disease: a postmortem study. Cellular and Molecular Neurobiology 1992, 12:581-587.
17. Oishi M., Mochizuki Y., Yoshihashi H., Takasu T., Nakano E. Laboratory examinations correlated with severity of dementia. Annals of Clinical and Laboratory Science 1996, 26:340-345.
18. Palmer A.M., Wilcock G.K., Esiri M.M., Francis P.T., Bowen D.M. Monoaminergic innervation of the frontal and temporal lobes in Alzheimer's disease. Brain Research 1987, 401:231-238.
19. Parnetti L., Gaiti A., Reboldi G.P., Santucci C., Mecocci P., Brunetti M., Cadini D., Senin U. CSF monoamine metabolites in old age dementias. Molecular Chemical Neuropathology 1992, 16:143-157.
20. Raskind M.A., Peskind E.R., Holmes C., Goldstein D.S. Patterns of cerebrospinal fluid catechols support increased central noradrenergic responsiveness in aging and Alzheimer's disease. Biological Psychiatry 1999, 46:756-765.
21. Reuster T., Rilke O., Oehler J. High correlation between salivary MHPG and CSF MHPG. Psychopharmacology (Berl) 2002, 162:415-418.
22. Sheline Y.I., Miller K., Bardgett M.E., Csernansky J.G. Higher cerebrospinal fluid MHPG in subjects with dementia of the Alzheimer type. Relationship with cognitive dysfunction. American Journal of Geriatric Psychiatry 1998, 6:155-161.
23. Storga D., Vrecko K., Birkmayer J.G., Reibnegger G. Monoaminergic neurotransmitters, their precursors and metabolites in brains of Alzheimer patients. Neuroscience Letters 1996, 203:29-32.
24. Tannenbaum B., Anisman H. Impact of chronic intermittent challenges in stressor-susceptible and resilient strains of mice. Biological Psychiatry 2003, 53:292-303.
25. Tohgi H., Ueno M., Abe T., Takahashi S., Nozaki Y. Concentrations of monoamines and their metabolites in the cerebrospinal fluid from patients with senile dementia of the Alzheimer type and vascular dementia of the Binswanger type. Journal of Neural Transmission. Parkinson's Disease and Dementia Section 1992, 4:69-77.
26. Unger J.M., van Belle G., Heyman A. Cross-sectional versus longitudinal estimates of cognitive change in nondemented older people: a CERAD study. Consortium to Establish a Registry for Alzheimer's Disease. Journal of American Geriatric Society 1999, 47:559-563.
27. Yajima j, Yamada S., Tsuda A. Determination of saliva free 3-methoxy-4-hydroxyphenylglycol in normal volunteers using gas chromatography-mass spectrometry. Biogenic Amines 2001, 16:173-183.
28. Yamada S., Yamauchi K., Yajima J., Hisadomi S., Maeda H., Toyomasu K., Tanaka M. Saliva level of free 3-methoxy-4-hydroxyphenylglycol (MHPG) as a biological index of anxiety disorders. Psychiatry Research 2000, 93:217-223.
29. Yang R.K., Yehuda R., Holland D.D., Knott P.J. Relationship between 3-methoxy-4-hydroxyphenylglycol and homovanillic acid in saliva and plasma of healthy volunteers. Biological Psychiatry 1997, 42:821-826.